Maravai LifeSciences (MRVI) Projected to Post Quarterly Earnings on Wednesday

Maravai LifeSciences (NASDAQ:MRVI) is projected to post its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Maravai LifeSciences to post earnings of ($0.07) per share and revenue of $49.0610 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 5:00 PM ET.

Maravai LifeSciences Trading Down 1.0%

MRVI opened at $2.93 on Wednesday. The stock has a market capitalization of $749.23 million, a price-to-earnings ratio of -3.49 and a beta of 0.39. The company has a quick ratio of 4.56, a current ratio of 5.29 and a debt-to-equity ratio of 0.74. Maravai LifeSciences has a twelve month low of $1.66 and a twelve month high of $4.40. The company has a 50-day simple moving average of $3.50 and a 200 day simple moving average of $3.16.

Insider Activity at Maravai LifeSciences

In related news, Director Gregory T. Lucier acquired 51,472 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was acquired at an average cost of $3.70 per share, for a total transaction of $190,446.40. Following the transaction, the director directly owned 106,595 shares in the company, valued at $394,401.50. This trade represents a 93.38% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.11% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in shares of Maravai LifeSciences by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company’s stock valued at $9,259,000 after acquiring an additional 34,447 shares during the last quarter. State Street Corp increased its holdings in Maravai LifeSciences by 1.1% in the 4th quarter. State Street Corp now owns 2,414,249 shares of the company’s stock worth $7,846,000 after purchasing an additional 27,219 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Maravai LifeSciences by 28.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,014,214 shares of the company’s stock valued at $6,546,000 after purchasing an additional 442,059 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Maravai LifeSciences by 52.3% during the fourth quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock valued at $6,501,000 after purchasing an additional 687,253 shares in the last quarter. Finally, Lazard Asset Management LLC grew its holdings in shares of Maravai LifeSciences by 6.2% during the third quarter. Lazard Asset Management LLC now owns 1,540,226 shares of the company’s stock worth $4,420,000 after purchasing an additional 89,805 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Wells Fargo & Company upped their price target on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a report on Monday, December 15th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.25.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.